(Reuters) – French vaccine maker Valneva said on Monday it sold the priority review voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million.
Valneva was awarded a tropical disease PRV in November 2023 for IXCHIQ, its single-dose vaccine for the prevention of disease caused by the chikungunya virus, the company said.
(Reporting by Michal Aleksandrowicz in Gdansk; Editing by Edmund Klamann)
Comments